Latest Content

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

From prior authorization delays to PBM reforms and Medicaid gaps, experts track policy shifts that shape health equity and health care access nationwide.

The authors call for policy reforms that could strengthen patient-provider relationships, support care innovation, and improve quality for Medicare beneficiaries.

Alopecia profoundly disrupts identity, emotional wellbeing, and social life, with many people struggling due to stigma, concealment pressures, and unmet psychological support needs.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Study links elevated serum haptoglobin to chronic spontaneous urticaria activity, suggesting it predicts treatment response and complete disease control.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.